Aspirin
Treatment for Ischemic Heart Disease
Typical Dosage: 75-100mg daily
Effectiveness
85%
Safety Score
80%
Clinical Trials
527
Participants
500K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
75-100mg daily
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
40(Treat 40 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$80
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$114
Comparison vs No treatment
Cost Difference
+$80/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Aspirin Outcomes
for Ischemic Heart Disease
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Common Side Effects
Gastrointestinal bleeding
+1%
Dyspepsia
+10%
Active Clinical Trials
1 active trial recruiting for Aspirin in Ischemic Heart Disease
Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
NCT05347069RECRUITINGPHASE4
2.89K participants
INTERVENTIONAL
Kyoto, Japan
Started: Jun 14, 2022
Completed Clinical Trials
16 completed trials for Aspirin in Ischemic Heart Disease
Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease
NCT02370680COMPLETEDPHASE1
41 participants
INTERVENTIONAL
Baltimore, United States
Started: Feb 1, 2015
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
NCT04097912COMPLETED
100K participants
OBSERVATIONAL
Multiple Locations, Germany +1 more
Started: Sep 30, 2019
Optimum Platelet Inhibition After Coronary Bypass Surgery
NCT00262275COMPLETEDNA
INTERVENTIONAL
Cambridge, United Kingdom
Started: Jul 1, 2002
Aspirin Resistance in Coronary Artery Disease
NCT00753935COMPLETEDEARLY_PHASE1
92 participants
INTERVENTIONAL
Nashville, United States
Started: Jun 1, 2006
Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents
NCT03056118COMPLETEDPHASE4
1.37K participants
INTERVENTIONAL
Started: May 2, 2011
Chronic Kidney Disease (CKD) Platelet Study
NCT03649711COMPLETEDPHASE3
76 participants
INTERVENTIONAL
Little Rock, United States +1 more
Started: Nov 1, 2018
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
NCT00041938COMPLETEDPHASE3
2.31K participants
INTERVENTIONAL
Tucson, United States +63 more
Started: Oct 1, 2002
Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
NCT03198741COMPLETEDPHASE4
783 participants
INTERVENTIONAL
Shenyang, China
Started: Jul 13, 2017
Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study
NCT01534026COMPLETEDPHASE4
12 participants
INTERVENTIONAL
Melbourne, Australia
Started: Mar 1, 2012
SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
NCT04418479COMPLETEDPHASE4
5.51K participants
INTERVENTIONAL
Seoul, South Korea
Started: Aug 10, 2020
Platelet Drug Trial in Coronary Disease Progression
NCT00000496COMPLETEDPHASE3
INTERVENTIONAL
Started: Dec 1, 1979
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
NCT00822536COMPLETEDPHASE4
1.8K participants
INTERVENTIONAL
Paris, France
Started: Jan 1, 2009
Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery
NCT02209909COMPLETEDNA
48 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jul 1, 2014
Aspirin-Myocardial Infarction Study (AMIS)
NCT00000491COMPLETEDPHASE3
INTERVENTIONAL
Started: Oct 1, 1974
Physicians' Health Study
NCT00000500COMPLETEDPHASE3
INTERVENTIONAL
Started: Sep 1, 1981
Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia
NCT00382421COMPLETEDNA
INTERVENTIONAL
Lucerne, Switzerland
Started: Feb 1, 1992
Showing 20 of 548 total trials